Table S1 from Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti–PD-1 Immunotherapy in Endometrial Carcinoma

Table S1 from Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti–PD-1 Immunotherapy in Endometrial Carcinoma

<p>Supplementary Table S1: Genomic and clinical characteristics of the study cohort.</p>

Αποθηκεύτηκε σε:

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριος συγγραφέας:	Ryan D. Chow (15109654) (author)
Άλλοι συγγραφείς:	Tai Michaels (15122331) (author), Stefania Bellone (15122334) (author), Tobias M.P. Hartwich (15122337) (author), Elena Bonazzoli (15122340) (author), Akiko Iwasaki (15122343) (author), Eric Song (15122346) (author), Alessandro D. Santin (15122349) (author)
Έκδοση:	2025
Θέματα:	Cancer Therapeutic Research and Development Immuno-oncology Gynecological Cancers Endometrial cancer Immunotherapy Translational Research
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια

Table S2 from Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti–PD-1 Immunotherapy in Endometrial Carcinoma
ανά: Ryan D. Chow (15109654)
Έκδοση: (2025)

Table S3 from Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti–PD-1 Immunotherapy in Endometrial Carcinoma
ανά: Ryan D. Chow (15109654)
Έκδοση: (2025)

Table S4 from Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti–PD-1 Immunotherapy in Endometrial Carcinoma
ανά: Ryan D. Chow (15109654)
Έκδοση: (2025)

Supplemental Table 1 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
ανά: Zannel Blanchard (16617018)
Έκδοση: (2025)

Supplemental Table 2 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
ανά: Zannel Blanchard (16617018)
Έκδοση: (2025)

Supplemental Table 3 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
ανά: Zannel Blanchard (16617018)
Έκδοση: (2025)

Figure 1 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas
ανά: Niccolò G. Santin (22229756)
Έκδοση: (2025)

Figure 2 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas
ανά: Niccolò G. Santin (22229756)
Έκδοση: (2025)

Figure 3 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas
ανά: Niccolò G. Santin (22229756)
Έκδοση: (2025)

Figure 4 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas
ανά: Niccolò G. Santin (22229756)
Έκδοση: (2025)

Figure 5 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas
ανά: Niccolò G. Santin (22229756)
Έκδοση: (2025)

Table 1 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas
ανά: Niccolò G. Santin (22229756)
Έκδοση: (2025)

Supplemental Figure 1 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas
ανά: Niccolò G. Santin (22229756)
Έκδοση: (2025)

Supplemental Figure 2 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas
ανά: Niccolò G. Santin (22229756)
Έκδοση: (2025)

Table 2_Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma.xlsx
ανά: Yumeng Cai (5591276)
Έκδοση: (2025)

Table 1_Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma.xlsx
ανά: Yumeng Cai (5591276)
Έκδοση: (2025)

Image 1_Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma.tif
ανά: Yumeng Cai (5591276)
Έκδοση: (2025)

Table 3_Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma.docx
ανά: Yumeng Cai (5591276)
Έκδοση: (2025)

Image 3_Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma.tif
ανά: Yumeng Cai (5591276)
Έκδοση: (2025)

Image 2_Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma.tif
ανά: Yumeng Cai (5591276)
Έκδοση: (2025)

Image 5_Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma.jpg
ανά: Yumeng Cai (5591276)
Έκδοση: (2025)

Image 4_Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma.tif
ανά: Yumeng Cai (5591276)
Έκδοση: (2025)

Image 6_Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma.tif
ανά: Yumeng Cai (5591276)
Έκδοση: (2025)

Image 7_Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma.tiff
ανά: Yumeng Cai (5591276)
Έκδοση: (2025)

Table 1_Evaluation of microsatellite instability patterns in mismatch repair deficiency: a retrospective analysis of 285 endometrial cancers.docx
ανά: Cheng Wang (102692)
Έκδοση: (2025)

Supplementary Figure 1 from Antitumor Effect of Farletuzumab Ecteribulin in Molecular Subtypes of Endometrial Cancer Patient-Derived Xenograft Models
ανά: Shigehiro Yagishita (15088446)
Έκδοση: (2025)

Supplementary Figure 2 from Antitumor Effect of Farletuzumab Ecteribulin in Molecular Subtypes of Endometrial Cancer Patient-Derived Xenograft Models
ανά: Shigehiro Yagishita (15088446)
Έκδοση: (2025)

Supplementary Figure 3 from Antitumor Effect of Farletuzumab Ecteribulin in Molecular Subtypes of Endometrial Cancer Patient-Derived Xenograft Models
ανά: Shigehiro Yagishita (15088446)
Έκδοση: (2025)

Supplementary Figure 4 from Antitumor Effect of Farletuzumab Ecteribulin in Molecular Subtypes of Endometrial Cancer Patient-Derived Xenograft Models
ανά: Shigehiro Yagishita (15088446)
Έκδοση: (2025)

Supplementary Table S4 from Evolution and Co-occurrence of PI3K Pathway Gene Mutations in Endometrial Carcinoma Molecular Subtypes at the Single-Cell Level
ανά: Arnaud Da Cruz Paula (17316230)
Έκδοση: (2025)

Immune checkpoint inhibitors or targeted therapy by mismatch repair status in endometrial cancer: a meta-analysis
ανά: Yi Tang (55726)
Έκδοση: (2025)

Figure S1 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
ανά: Martina S.J. McDermott (15206951)
Έκδοση: (2025)

Figure S2 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
ανά: Martina S.J. McDermott (15206951)
Έκδοση: (2025)

Figure S3 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
ανά: Martina S.J. McDermott (15206951)
Έκδοση: (2025)

Figure S4 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
ανά: Martina S.J. McDermott (15206951)
Έκδοση: (2025)

Figure S5 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
ανά: Martina S.J. McDermott (15206951)
Έκδοση: (2025)

Figure S6 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
ανά: Martina S.J. McDermott (15206951)
Έκδοση: (2025)

Figure S7 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
ανά: Martina S.J. McDermott (15206951)
Έκδοση: (2025)

Figure S8 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
ανά: Martina S.J. McDermott (15206951)
Έκδοση: (2025)

Supplemental Tables 1 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
ανά: Martina S.J. McDermott (15206951)
Έκδοση: (2025)